Gorgojo-MartÃnez, J.J.; Gargallo-Fernández, M.A.; Galdón Sanz-Pastor, A.; Antón-Bravo, T.; Brito-Sanfiel, M.; Wong-Cruz, J.
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. J. Clin. Med. 2020, 9, 2275.
https://doi.org/10.3390/jcm9072275
AMA Style
Gorgojo-MartÃnez JJ, Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J.
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. Journal of Clinical Medicine. 2020; 9(7):2275.
https://doi.org/10.3390/jcm9072275
Chicago/Turabian Style
Gorgojo-MartÃnez, Juan J., Manuel A. Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Miguel Brito-Sanfiel, and Jaime Wong-Cruz.
2020. "Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study" Journal of Clinical Medicine 9, no. 7: 2275.
https://doi.org/10.3390/jcm9072275
APA Style
Gorgojo-MartÃnez, J. J., Gargallo-Fernández, M. A., Galdón Sanz-Pastor, A., Antón-Bravo, T., Brito-Sanfiel, M., & Wong-Cruz, J.
(2020). Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. Journal of Clinical Medicine, 9(7), 2275.
https://doi.org/10.3390/jcm9072275